Driver oncogenes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ros oncogene 1 (ROS1) have been identified in the tumors of patients with non-small cell lung cancer (NSCLC), and targeted therapy results in a longer progression-free survival than cytotoxic chemotherapy [1–3]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.